Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.

NCT04333914 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT04333914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Completed
Start date
April 15, 2020
Completion date
December 31, 2021
Enrollment
19 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic hematological or solid tumor, sars-cov-2 (covid-19) infection